Bladder Cancer Therapeutics: Market Research Report

October 2010 | 580 pages | ID: BDA9EBF7800EN
Global Industry Analysts, Inc

Abstracts

This report analyzes the worldwide markets for Bladder Cancer Therapeutics in US$ Million.

The report provides separate comprehensive analytics for US, Japan, Europe, and Rest of World.

Annual estimates and forecasts are provided for the period 2007 through 2015.

A six-year historic analysis is also provided for these markets.

The report profiles 62 companies including many key and niche players such as Affitech A/S, Allergan, Inc., Allos Therapeutics, Inc., Astellas Pharma, Inc., Astrazeneca Plc, AVI BioPharma, Inc., BioCancell Therapeutics, Inc., Bioniche Life Sciences, Inc., Bristol-Myers Squibb Company, Celldex Therapeutics, Inc., Cytavis BioPharma GMBH, Eli Lilly and Company, Endo Pharmaceuticals Holdings, Inc., ENKAM Pharmaceuticals A/S, F.Hoffmann-la Roche Ltd., Halozyme Therapeutics, Inc., Laboratoires Pierre Fabre SA, NatImmune A/S, Oncogenex Pharmaceuticals, Inc., OncoTherapy Science, Inc., Sanofi-Aventis, Spectrum Pharmaceuticals, Inc., Telormedix SA, and Viventia Biotechnologies, Inc.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.

Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1.INDUSTRY OVERVIEW

Introduction
Bladder Cancer Growing at an Alarming Rate
Bladder Cancer Statistics

Table 1. Worldwide Incidence of Bladder Cancer by Select Countries/Region (2003 & 2013): US, Europe, and Japan (In '000s) (includes corresponding Graph/Chart)

Table 2. Worldwide Incidence and Mortality Rates of Select Cancer Types in Males: 2007 (includes corresponding Graph/Chart)

Table 3. Incidence and Mortality Rates of Select Cancer Types in Industrialized Countries: 2007 (includes corresponding Graph/Chart)

Table 4. Incidence and Mortality Rates of Select Cancer Types in Developing Markets: 2007 (includes corresponding Graph/Chart)

Recurrent Nature: A Major Cause of Concern
Bladder Cancer: The Most Costly Cancer To Treat
Generics Characterize Bladder Cancer Market
Existing Drug Therapies Lack in Assuring Long Term Survival Rate
Approved Intravesical Agents for Bladder Cancer
Bladder Cancer Demands New Therapeutics to Fill the Void

Table 5. Number of Pipeline Drugs by Select Cancer Types (includes corresponding Graph/Chart)

What the Future Holds?

Table 6. World Market for Bladder Cancer Therapeutics (2008): Percentage Share Breakdown of Total Number of Drugs by Development Stage (includes corresponding Graph/Chart)

Emerging Therapeutic Options for Superficial Bladder Cancer

Table 7. EOquin Penetration Rate in the US for the Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 8. US Market for EOquin: Annual Revenue Projections for the Years 2011 through 2015 in US$ Million (includes corresponding Graph/Chart)

Registration Process for New Drugs: A Review
Competitive Landscape
Leading Therapeutics in Global Bladder Cancer Market
Select Companies Involved in Late-Stage Bladder Cancer Clinical Trials
Select Companies Involved in Phase-II Clinical Trials
Select Companies Involved in Phase-I Clinical Trials
Select Companies Involved in Pre-clinical Stage
Current and Future Analysis

2.MAJOR TRENDS & ISSUES

Cigarette Smoking and Carcinogenic Substances: The Major Culprits
Men at High Risk than Women
New Therapeutics for Elderly Population: Need of the Hour
Lasers for Bladder Cancer Treatment: An Evolving Approach
Photodynamic Therapy (PDT) Holds Potential
SonoPhoto Dynamic Therapy – A New Treatment for Non-Invasive Bladder Cancer

3.BLADDER CANCER TREATMENT

Non-Invasive (Superficial) Bladder Cancer Treatment
Treatment Options and Potential Side Effects
Surgery
Immunotherapy
Intravesical Chemotherapy
Invasive Bladder Cancer Treatment
Treatment Options, and Potential Side Effects
Surgery
Cystectomy
Partial Cystectomy – A Part of Bladder is Removed
Radical Cystectomy – Entire Bladder is Removed
Side Effects of Removing the Bladder
What’s the Solution if the Bladder Is Removed?
Reconstructive Surgery
Continent Urinary Diversion or Ileal Loop Diversion
Neobladder
Radiotherapy
Systemic Chemotherapy
Metastatic Bladder Cancer
Palliative Treatment
Other Treatment Options
Targeted Therapy
Gene Therapy
Chemoprevention
Chemoradiotherapy
Photodynamic Therapy (PDT)
Complementary Therapies

4.MAJOR BLADDER CANCER DRUGS

A Quick Market Primer
Leading Bladder Cancer Therapeutics
Select Bladder Cancer Therapeutics in Pipeline: 2009
Approved Bladder Cancer Drugs
Thiotepa
Adriamycin (Doxorubican hydrochloride)
Methotrexate
Vinblastine
Epirubicin
Mitomycin C
Mitoxzantrone
Oxaliplatin
IL2 (Aldesleukin) and Interferon into the Bladder
Keyhole Limpet Haemocyanin (KLH)
Platinol-AQ (Cisplatin)
Gemzar (Gemcitabine)
OncoTICE/TICE BCG
PACIS™ BCG
Valstar (valrubicin)
Late-Stage Pipeline Drugs
EOquin (Apaziquone)
Urocidin (MCC)
Larotaxel (XRP-9881)
Javlor® (Vinflunine)
4-HPR (FENRETINIDE)
Pipeline Analysis of Other Potential Drugs
BEXIDEM [On-Hold]
BC-819 [Phase IIb]
CDX-1307 [Phase I]
Chemophase® [Phase I/IIa]
PDX [Pralatrexate] [Phase II]
OGX-427 [Phase I]
OGX-011 [Phase II]
Celebrex (Celecoxib) [Phase IIb/III]
TMX-101 [Pre-Clinical Stage]
AGSPSCA [Phase Ib]
Iressa with Gemzar [Phase II]
MDR09521[Development Stage]
siRNA ALPHAGEN [Development Stage]

5.AN OVERVIEW OF BLADDER CANCER

Cancer – An Insight
Factors Causing Cancer Ranked in Order of Impact
Cancer Diagnosis
Treatment Strategies for Cancer
Progressing R&D Efforts to Innovate Drug Delivery for Cancer Treatment
The Human Bladder: A Urine Storing Organ
Bladder Cancer – Introduction
Classification of Bladder Cancer
Non-Invasive Cancer
Invasive Cancer
Types of Bladder Cancer
Transitional Cell Carcinoma/Urothelial Carcinoma
Squamous Cell Carcinoma
Adenocarcinoma

Table 9. US Prevalence of Bladder Cancer by Type (includes corresponding Graph/Chart)

Major Risk Factors
Controllable Risk Factors
Uncontrollable Risk Factors
Symptoms and Diagnosis
Symptoms
Diagnosis
General Diagnostic Tests
Blood Tests
Physical Examination
Urine Test
Prescribed Procedure to Locate Bladder Cancer
Cytoscopy and Biopsy
Intravenous Pyelogram (IVP)
Ultrasound Scanning
Test/Procedures to Confirm Cancer Penetration
CT Scan
Radioisotope Bone Scan
Staging and Grading of Bladder Cancer: Crucial for Treatment
Staging
Grading

6.RESEARCH & DEVELOPMENT

Variations in PSCA Gene Increase Risk of Bladder Cancer
Genetic Analysis for Assaying Bladder Cancer Recurrence
Selenium Allays the Risk of Bladder Cancer
Individuals with Common Genome Variants at Increased Risk of Developing Bladder Cancer
New Studies Reveal Correlation Between Coffee and Bladder Cancer
Raw Cruciferous Vegetables Alleviates the Risk of Bladder Cancer
Broccoli Sprouts a Super-Food to Prevent Bladder Cancer
Well Water Counts to the Risk Factors for the Bladder cancer
Frankincense Oil: Potentially a Future Aid for Bladder Cancer
SRC Gene Suppresses Bladder Cancer Metastases

7.FDA APPROVALS AND FILINGS

Allos Therapeutics Obtains FDA Orphan Drug Designation for Pralatrexate
Aeterna Zentaris Secures FDA Approval for IND Application of AEZS-108
Biocancell Obtains FDA Clearance to Continue Clinical Trial for BC-819
Bioniche to Commence Additional Phase III Clinical Trial of Urocidin™
Bioniche Obtains FDA Approval for Phase III Trial of Urocidin
FDA Grants Fast Track Designation for Apaziquone (EOquin®)
Indevus Receives FDA Nod for Valstar
Biocancell Obtains FDA Approval of BC-819 for Phase IIb Clinical Trail

8.RECENT INDUSTRY ACTIVITY

MDRNA Takes Over Cequent Pharmaceuticals
MDRNA Changes Name to Marina Biotech
Telormedix Commences Phase I/II clinical Trial for TMX-101
Spectrum and Handok Ink Joint Marketing Agreement for Apaziquone in Korea
MDRNA Expands and Extends Collaboration with VPC
Endo Pharmaceuticals Acquires Indevus Pharmaceuticals
Affitech Merges with Pharmexa
Takeda America Holdings Acquires IDM Pharma
Schering-Plough Merges with Merck
Cell Genesys Merges with BioSante Pharmaceuticals
Celldex Therapeutics Acquires CuraGen
EMEA Grants Orphan Medicinal Product Designation for Pralatrexate
Endo Pharmaceuticals Obtains License for Urocidin
CHMP Issues Positive Opinion on JAVLOR® to Treat Metastatic Bladder Cancer
BioCis Pharma Initiates Phase I Clinical Trial of ProtoCure™
Sonus Pharmaceuticals Acquires OncoGenex Technologies
Callisto Merges with Celldex Therapeutics
Allergan and Spectrum Pharmaceuticals Collaborate for Apaziquone
Pro-Pharmaceuticals and BioCancell Collaborate to Administer siRNA for H19 Genes Destruction in Cancerous Cells
AVANT Adopts New Identity as Celldex Therapeutics
Lorus Therapeutics Receives New Patent for LOR-2040, Leukemia Drug
Spectrum Pharmaceuticals Obtains Canadian Authorities Approval for Phase III Clinical Trial of EOquin
NCCN Obtains Grant to Evaluate Cetuximab Efficacy in Bladder Cancer
Allos Therapeutics Commences Phase II Trials for Pralatrexate
Halozyme Announces Status Update of Chemophase® Phase I/IIa Clinical Trial
Spectrum Pharmaceuticals Establishes New Company in Canada
China Medical Technologies Acquires FISH Business
Peregrine Acquires Global License for Anti-Angiogenesis Technology
Bristol-Myers Terminates Partnership with Pierre Fabre

9.FOCUS ON SELECT GLOBAL PLAYERS

Affitech A/S (Denmark)
Allergan, Inc. (USA)
Allos Therapeutics, Inc. (USA)
Astellas Pharma, Inc. (Japan)
Astrazeneca Plc. (UK)
AVI BioPharma, Inc. (USA)
BioCancell Therapeutics, Inc. (Israel)
Bioniche Life Sciences, Inc. (Canada)
Bristol-Myers Squibb Company (USA)
Celldex Therapeutics, Inc. (USA)
Cytavis BioPharma GmbH (Germany)
Eli Lilly and Company (USA)
Endo Pharmaceuticals Holdings, Inc. (USA)
ENKAM Pharmaceuticals A/S (Denmark)
F. Hoffmann-La Roche Ltd. (Switzerland)
Halozyme Therapeutics, Inc. (USA)
Laboratoires Pierre Fabre SA (France)
NatImmune A/S (Denmark)
Oncogenex Pharmaceuticals, Inc. (USA)
OncoTherapy Science, Inc. (Japan)
Sanofi-Aventis (France)
Spectrum Pharmaceuticals, Inc. (USA)
Telormedix SA (Switzerland)
Viventia Biotechnologies, Inc. (Canada)

10.GLOBAL MARKET PERSPECTIVE

Table 10. World Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed by Annual Revenues in US$ Million for the Years 2007 through 2015 (includes corresponding Graph/Chart)

Table 11. World Historic Review for Bladder Cancer Therapeutics by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed by Annual Revenues in US$ Million for the Years 2001 through 2006 (includes corresponding Graph/Chart)

Table 12. World 11-Year Perspective for Bladder Cancer Therapeutics by Geographic Region – Percentage Breakdown of Revenues for US, Japan, Europe, and Rest of World Markets for the Years 2005, 2010 & 2015 (includes corresponding Graph/Chart)

III. MARKET

1.UNITED STATES

A. MARKET ANALYSIS

Bladder Cancer & Prevalence – A Recapitulation of Facts
Mortality Rates Higher in African Americans

Table 13. Incidence of Bladder Cancer Among African Americans (Males): Percentage Share Breakdown by Select Cancer/Type or Site and Gender for the Year 2007 (includes corresponding Graph/Chart)

Bladder Cancer - A Costly Urologic Condition

Table 14. Urologic Disease Costs in the US: 2006 (includes corresponding Graph/Chart)

US Bladder Cancer Statistics

Table 15. Bladder Cancer Prevalence and Mortality in the US by Gender: Percentage Share Breakdown for 2009

Table 16. Bladder Cancer Incidence in the US by Gender: Percentage Share Breakdown for 2008

FDA Approval
Strategic Corporate Developments
Select Players
Allergan, Inc.
Allos Therapeutics, Inc.
AVI BioPharma, Inc.
Bristol-Myers Squibb Company
Celldex Therapeutics, Inc.
Eli Lilly and Company
Endo Pharmaceuticals Holdings, Inc.
Halozyme Therapeutics, Inc.
Marina Biotech, Inc.
Oncogenex Pharmaceuticals, Inc.
Peplin, Inc.
Polyphenon Pharma
Spectrum Pharmaceuticals, Inc.

B. MARKET ANALYTICS

Table 17. US Recent Past, Current and Future Analysis for Bladder Cancer Therapeutics - Annual Revenues in US$ Million for the Years 2007 through 2015 (includes corresponding Graph/Chart)

Table 18. US Historic Review for Bladder Cancer Therapeutics - Annual Revenues in US$ Million for the Years 2001 through 2006 (includes corresponding Graph/Chart)

2.JAPAN

A. MARKET ANALYSIS

Current & Future Analysis
Select Players
alphaGEN, Co., Ltd
Astellas Pharma, Inc.
Nippon Kayaku Co., Ltd
OncoTherapy Science, Inc.

B. MARKET ANALYTICS

Table 19. Japanese Recent Past, Current and Future Analysis for Bladder Cancer Therapeutics – Annual Revenues in US$ Million for the Years 2007 through 2015 (includes corresponding Graph/Chart)

Table 20. Japanese Historic Review for Bladder Cancer Therapeutics - Annual Revenues in US$ Million for the Years 2001 through 2006 (includes corresponding Graph/Chart)

3.EUROPE

A. MARKET ANALYSIS

Current & Future Analysis
Bladder Cancer – Prevalence

Table 21. Bladder Cancer Incidence in Europe by Region (2006) for Germany, Italy, Spain, France, The UK, Scandinavia, and Benelux (includes corresponding Graph/Chart)

Table 22. Bladder Cancer Mortality in Europe by Region (2006) for Germany, Italy, the UK, Spain, France, Benelux, and Scandinavia (includes corresponding Graph/Chart)

Europe Lacks R&D Innovation in Bladder Cancer Market
Focus on Select Regional Market
United Kingdom
Bladder Cancer Prevalence – A Review
Bladder Cancer Statistics in the UK

Table 23. Incidence, Mortality, and Five-Year Survival Rate of Bladder Cancer in UK by Gender: 2006

Table 24. Bladder Cancer Incidence by Region (2006) for England, Wales, Scotland, and Northern Ireland (includes corresponding Graph/Chart)

Table 25. Age-Specific Incidence of Bladder Cancer by Gender: 2006 (includes corresponding Graph/Chart)

Table 26. Number of Bladder Cancer Deaths in the UK (2007): Breakdown by Region - England, Wales, Scotland, and Northern Ireland (includes corresponding Graph/Chart)

Table 27. Age-Specific Bladder Cancer Mortality Rate in UK Males: Breakdown by Age Group for 2007 (includes corresponding Graph/Chart)

Table 28. Age-Specific Bladder Cancer Mortality Rate in UK Females: Breakdown by Age Group for 2007 (includes corresponding Graph/Chart)

Strategic Corporate Developments
Select Players
Affitech A/S (Denmark)
Astrazeneca PLC (UK)
BioCis Pharma Ltd (Finland)
Cambridge Laboratories Ltd. (UK)
curasan AG (Germany)
Cytavis BioPharma GmbH (Germany)
ENKAM Pharmaceuticals A/S (Denmark)
F. Hoffmann-La Roche Ltd. (Switzerland)
Laboratoires Pierre Fabre SA (France)
NatImmune A/S (Denmark)
Sanofi-Aventis (France)
Telormedix SA (Switzerland)

B. MARKET ANALYTICS

Table 29. European Recent Past, Current and Future Analysis for Bladder Cancer Therapeutics – Annual Revenues in US$ Million for the Years 2007 through 2015 (includes corresponding Graph/Chart)

Table 30. European Historic Review for Bladder Cancer Therapeutics - Annual Revenues in US$ Million for the Years 2001 through 2006 (includes corresponding Graph/Chart)

4.REST OF WORLD

A. MARKET ANALYSIS

Current & Future Analysis
Select Markets
Canada
Bladder Cancer Treatment
Bladder Cancer Statistics

Table 31. Bladder Cancer New Cases in Canada: Percentage Share Breakdown by Gender for 2009

Table 32. Bladder Cancer Mortality in Canada: Percentage Share Breakdown by Gender for 2009

Table 33. New Cases of Cancer Among Canadian Females by Type: Percentage Share Breakdown for 2009 (includes corresponding Graph/Chart)

Table 34. Cancer Mortality Among Canadian Females by Cancer Type: Percentage Share Breakdown for 2009 (includes corresponding Graph/Chart)

Table 35. New Cases of Cancer Among Canadian Males by Type: Percentage Share Breakdown for 2009 (includes corresponding Graph/Chart)

Table 36. Cancer Mortality among Canadian Males by Cancer Type: Percentage Share Breakdown for 2009 (includes corresponding Graph/Chart)

Asia-Pacific
China
India
Australia
Women at Increased Risk Over Men in Australia – A New Finding

Table 37. Number of Deaths Due to Bladder Cancer: Breakdown by Age Group for the Year 2006 (includes corresponding Graph/Chart)

Table 38. Age-Standardized Mortality Rate Due to Bladder Cancer in Australia: Breakdown by Age Group for the Year 2006 (includes corresponding Graph/Chart)

Table 39. Number of Deaths Due to Bladder Cancer (Males): Breakdown by Age Group for the Year 2006 (includes corresponding Graph/Chart)

Table 40. Number of Deaths Due to Bladder Cancer (Females): Breakdown by Age Group for the Year 2006 (includes corresponding Graph/Chart)

South Africa – Prevalence
FDA Approval
Strategic Corporate Developments
Select Players
BioCancell Therapeutics, Inc. (Israel)
Bioniche Life Sciences, Inc. (Canada)
China Medical Technologies Inc. (China)
Lorus Therapeutics, Inc. (Canada)
PharmaGap, Inc. (Canada)
Viventia Biotechnologies, Inc. (Canada)

B. MARKET ANALYTICS

Table 41. Rest of World Recent Past, Current and Future Analysis for Bladder Cancer Therapeutics – Annual Revenues in US$ Million for the Years 2007 through 2015 (includes corresponding Graph/Chart)

Table 42. Rest of World Historic Review for Bladder Cancer Therapeutics - Annual Revenues in US$ Million for the Years 2001 through 2006 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 62 (including Divisions/Subsidiaries - 67)
Region/CountryPlayers
The United States28
Canada
Japan
Europe21
France
Germany
The United Kingdom
Spain
Rest of Europe
Asia-Pacific (Excluding Japan)
Middle-East